Free tool
FAERS Monitor: Tobi Podhaler
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201688 or its brand name (Tobi Podhaler, Tobramycin). Reports on generic versions are filed under their own applications.
Reports
15,248
Serious
12,015
79% of reports
Hospitalization
7,351
Death reported
1,542
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea931
- pneumonia927
- off label use899
- cough847
- infective pulmonary exacerbation of cystic fibrosis842
- cystic fibrosis778
- condition aggravated743
- drug ineffective742
- death717
- acute kidney injury691
- hospitalisation691
- infection511
- pyrexia495
- fatigue451
- malaise450
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 80 |
| 2005 | 97 |
| 2006 | 76 |
| 2007 | 124 |
| 2008 | 90 |
| 2009 | 99 |
| 2010 | 101 |
| 2011 | 208 |
| 2012 | 213 |
| 2013 | 288 |
| 2014 | 659 |
| 2015 | 1,050 |
| 2016 | 857 |
| 2017 | 736 |
| 2018 | 1,177 |
| 2019 | 1,878 |
| 2020 | 1,727 |
| 2021 | 1,152 |
| 2022 | 1,047 |
| 2023 | 883 |
| 2024 | 1,087 |
| 2025 | 925 |
| 2026 | 694 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,911 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 842 | 252.2 | 234.8 | 177,968 |
| cystic fibrosisSignal | 778 | 225.3 | 209.2 | 149,208 |
| acute kidney injurySignal | 691 | 6.3 | 5.8 | 3,052 |
| hospitalisationSignal | 691 | 6.2 | 5.8 | 3,035 |
| infectionSignal | 511 | 4.9 | 4.5 | 1,580 |
| coughSignal | 847 | 4.2 | 3.9 | 2,064 |
| pneumoniaSignal | 927 | 4.0 | 3.7 | 2,072 |
| condition aggravatedSignal | 743 | 3.4 | 3.1 | 1,256 |
| dyspnoeaSignal | 931 | 2.3 | 2.1 | 678 |
| pyrexia | 495 | 2.0 | 1.8 | 241 |
| off label use | 899 | 1.4 | 1.3 | 114 |
| malaise | 450 | 1.4 | 1.3 | 56 |
| death | 717 | 1.1 | 1.1 | 14 |
| fatigue | 451 | 0.8 | 0.7 | 23 |
| drug ineffective | 742 | 0.8 | 0.7 | 51 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.